Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pharmacol., 17 September 2025

Sec. Integrative and Regenerative Pharmacology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1597755

Correction: Resveratrol and Angiogenin-2 combined with PEGDA/TCS hydrogel for the targeted therapy of hypoxic bone defects via activation of the autophagy pathway

This article is a correction to:

  1. Resveratrol and Angiogenin-2 Combined With PEGDA/TCS Hydrogel for the Targeted Therapy of Hypoxic Bone Defects via Activation of the Autophagy Pathway

    1. Read original article
Dehui Fan&#x;Dehui Fan1†Hengping Liu&#x;Hengping Liu2†Zhenning ZhangZhenning Zhang1Meiyi SuMeiyi Su1Zhixian YuanZhixian Yuan1Ying LinYing Lin1Shuquan YangShuquan Yang1Wenqiang Li Wenqiang Li3*Xintao Zhang Xintao Zhang4*
  • 1The Fifth Clinical College of Guangzhou University of Chinese Medicine Guangzhou, Guangdong Second Traditional Chinese Medicine Hospital, Guangzhou, China
  • 2Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
  • 3Engineering Technology Research Center for Sports Assistive Devices of Guangdong, Guangzhou Sport University, Guangzhou, China
  • 4Department of Sports Medicine and Rehabilitation, National and Local Joint Engineering, Research Center of Orthopaedic Biomaterials, Peking University Shenzhen Hospital, Shenzhen, China

A Correction on
Resveratrol and Angiogenin-2 combined with PEGDA/TCS hydrogel for the targeted therapy of hypoxic bone defects via activation of the autophagy pathway

by Fan D, Liu H, Zhang Z, Su M, Yuan Z, Lin Y, Yang S, Li W and Zhang X (2021). Front. Pharmacol. 12:618724. doi: 10.3389/fphar.2021.618724

In the published article, there was an error in Figures 3B, 4A,B as published. Images from different groups were stored in the same folder during image shooting, resulting in the misuse of images. The corrected Figures 3B, 4A,B and their captions appear below.

Figure 3
Composite image presenting experimental results. Panel A shows fluorescence microscopy images of cells with LC3 protein marked, indicating autophagy. Panel B displays fluorescently stained cell cultures. Panel C includes flow cytometry histograms depicting cell cycle phase distributions. Panel D presents scatter plots from flow cytometry to evaluate apoptosis. Panel E contains a bar chart summarizing cell cycle phase distributions in percentage. Panel F presents a bar chart illustrating percentages of early and late apoptosis. The variables assessed include the presence of Res and 3-MA.

Figure 3. CLSM observation of LC3 puncta (A), AO-EB staining (B), flow cytometry analysis of the cell cycle (C), apoptosis (D), and statistical analysis of the cell cycle (E), and apoptosis (F). The values are represented as the mean ± SD (n = 3). *p < 0.05, **p < 0.01 vs. control (without Res and 3-MA).

Figure 4
Panel A displays four microscopic images showing cellular morphology under different treatment conditions with Resveratrol (Res) and 3-Methyladenine (3-MA). Panel B displays four staining results of calcium deposits in cells under similar conditions. Panel C is a bar graph illustrating mRNA expression levels of Runx2, with significant increases under Res treatment. Panel D shows mRNA expression levels of OPN, and Panel E shows quantitative expression of calcium, both indicating increases with Res treatment. Bars are labeled with statistical significance markers.

Figure 4. Osteogenic differentiation of BMSCs treated with Res and 3-MA for 14 days. ALP activity detection (A) and ARS staining (B). mRNA expression of Runx2 (C) and OPN (D) detected by q-PCR. The quantative data of Ca nodulus analyzed by ARS staining using ImageJ software (E). The values are represented as the mean ± SD (n = 3). *p < 0.05, **p < 0.01 vs. control (without Res and 3-MA); #p < 0.05, ##p < 0.01 vs. Res group.

In the published article, there was an error in Figures 7A, 8 as published. The H&E, Masson, OCN and CD31 staining images of the animal tissue sections in Figures 7, 8 overlap with those used in our previous published study. This occurred because the animal experiments for both research projects were conducted concurrently, leading to inadvertent misplacement of data files. The corrected Figures 7A, 8 and their captions appear below.

Figure 7
Panel A shows histological images, both HE and CD31 staining, depicting vessel formation under different conditions with ANG2, Res, and 3-MA combinations. Bars represent 100 micrometers. Panels B and C display bar graphs of newly-formed vessel density and the number of vessels, respectively, under the same conditions, highlighting significant differences marked by asterisks and hashes.

Figure 7. Histological analysis (A) of bone defects via H&E staining and CD31 immunofluorescence staining. (B) The newly formed vessel density and (C) number were determined. The values are represented as the mean ± SD (n = 6).*p < 0.05, **p < 0.01 vs. ANG2 group; #p < 0.05, ##p < 0.01 vs. ANG2/Res group.

Figure 8
Histological image panels showing staining results under different conditions. The top row (Masson) has red and blue staining indicating fibrous tissue. The middle row (OCN) shows brown areas indicating osteocalcin presence. The bottom row (CD31) features light staining for endothelial cells. Each column represents varying treatments with ANG2, Res, and 3-MA. Scale bars are 200 micrometers.

Figure 8. Masson staining and immunohistochemical staining for OCN and CD31 in the bone defect area at the 8th week. The values are represented as the mean ± SD (n = 6).

The original article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: resveratrol, ANG2, autophagy, hypoxia condition, vascularization, bone defect

Citation: Fan D, Liu H, Zhang Z, Su M, Yuan Z, Lin Y, Yang S, Li W and Zhang X (2025) Correction: Resveratrol and Angiogenin-2 combined with PEGDA/TCS hydrogel for the targeted therapy of hypoxic bone defects via activation of the autophagy pathway. Front. Pharmacol. 16:1597755. doi: 10.3389/fphar.2025.1597755

Received: 21 March 2025; Accepted: 25 June 2025;
Published: 17 September 2025.

Edited and reviewed by:

Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa

Copyright © 2025 Fan, Liu, Zhang, Su, Yuan, Lin, Yang, Li and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wenqiang Li, Z3p0eWx3cUBmb3htYWlsLmNvbQ==, NDA1MTE5OTIzQHFxLmNvbQ==; Xintao Zhang, emhhbmd4aW50YW9Ac2luYS5jb20=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.